Reservoir Neuroscience Secures $4M Funding for Innovative Brain Health Therapies

Reservoir Neuroscience Secures $4M Funding for Innovative Brain Health Therapies

Reservoir Neuroscience, a San Francisco-based biotech company, has recently concluded a successful financing round, raising $4 million to advance its groundbreaking therapies for age-related neurodegeneration. The funds will be primarily used to support the development of a novel class of drug compounds aimed at rejuvenating the brain’s blood vessels and restoring brain health.

The financing round was led by Kizoo Technology Capital, a prominent investor in rejuvenation biotech. Kizoo focuses on supporting startups that are actively working to reverse age-related damage at the cellular and molecular level. Additionally, previous investors R42 Fund and Healthspan Ventures also participated in the round.

Reservoir Neuroscience’s pioneering approach to neurodegeneration was developed by co-founders Aaron Friedman and Vlad Senatorov, both PhD neuroscientists from UC Berkeley. Their research centers around understanding the impact of aging blood vessels on brain health. The company’s ultimate goal is to develop a groundbreaking drug that specifically targets vascular disease, effectively restoring brain health during the natural aging process and in age-related diseases.

What sets Reservoir Neuroscience apart is its innovative use of organ-on-chip technology. Through this cutting-edge method, the company has been able to grow human blood vessels and study vascular aging in a controlled laboratory environment. This research has led to the discovery and development of a unique compound that has demonstrated the ability to reverse disease in blood vessels and repair the damaged blood-brain barrier.

Reservoir Neuroscience’s therapeutic strategy is focused on restoring the health of blood vessels, thereby reversing degenerative damage that spreads from the blood vessels to the brain. By tackling the underlying vascular problems that often arise with aging, the company aims to address the key risk factor for developing neurodegenerative diseases.

“We believe that Reservoir’s novel approach to restoring the health of the brain’s blood vessels, while also repairing the blood-brain barrier, has the potential to address the root causes of several neurological pathologies,” says Patrick Burgermeister, Partner of Kizoo Technology Capital and newly appointed board member of Reservoir Neuroscience.

Reservoir Neuroscience’s groundbreaking research has the potential to revolutionize the treatment of age-related neurodegeneration and other related diseases. By targeting vascular pathology, the company aims to improve brain health, offering hope to millions of people worldwide. With the recent funding secured, Reservoir Neuroscience is well-positioned to further advance its innovative therapies and make a significant impact in the field of neuroscience.

FAQ:

1. What is Reservoir Neuroscience?
Reservoir Neuroscience is a biotech company based in San Francisco that focuses on developing therapies for age-related neurodegeneration.

2. What did Reservoir Neuroscience recently conclude?
Reservoir Neuroscience recently concluded a successful financing round, raising $4 million to advance its groundbreaking therapies.

3. What will the funds be used for?
The funds will be primarily used to support the development of a novel class of drug compounds aimed at rejuvenating the brain’s blood vessels and restoring brain health.

4. Who led the financing round?
The financing round was led by Kizoo Technology Capital, a prominent investor in rejuvenation biotech. Previous investors R42 Fund and Healthspan Ventures also participated.

5. Who are the co-founders of Reservoir Neuroscience?
The co-founders of Reservoir Neuroscience are Aaron Friedman and Vlad Senatorov, both PhD neuroscientists from UC Berkeley.

6. What is Reservoir Neuroscience’s research focused on?
Reservoir Neuroscience’s research focuses on understanding the impact of aging blood vessels on brain health and developing a groundbreaking drug that targets vascular disease.

7. How does Reservoir Neuroscience use organ-on-chip technology?
Reservoir Neuroscience utilizes organ-on-chip technology to grow human blood vessels and study vascular aging in a controlled laboratory environment.

8. What has Reservoir Neuroscience discovered through its research?
Through their research, Reservoir Neuroscience has discovered a unique compound that can reverse disease in blood vessels and repair the damaged blood-brain barrier.

9. What is Reservoir Neuroscience’s therapeutic strategy?
Reservoir Neuroscience’s therapeutic strategy is focused on restoring the health of blood vessels to reverse degenerative damage that spreads to the brain, targeting the underlying vascular problems associated with aging.

10. What potential impact does Reservoir Neuroscience’s research have?
Reservoir Neuroscience’s groundbreaking research has the potential to revolutionize the treatment of age-related neurodegeneration and other related diseases by improving brain health and addressing the root causes of neurological pathologies.

Key terms:

1. Neurodegeneration – The progressive loss of structure or function of neurons, including diseases such as Alzheimer’s and Parkinson’s.
2. Vascular disease – Conditions that affect the blood vessels, such as atherosclerosis or hypertension.
3. Blood-brain barrier – The protective barrier that separates the blood vessels from the brain tissue, regulating the passage of substances into the brain.

Suggested related links:
1. Reservoir Neuroscience – Official Website
2. Kizoo Technology Capital
3. R42 Fund
4. Healthspan Ventures

All Rights Reserved 2021
| .
Privacy policy
Contact